Egypt - English - EDA (Egyptian Drug Authority)

european egyptian pharm. ind. - tablet - 20 mg

Egypt - English - EDA (Egyptian Drug Authority)

european egyptian pharm. ind. - syrup - 5 mg/5ml

Egypt - English - EDA (Egyptian Drug Authority)

european egyptian pharm. ind. - syrup - 15 mg/5ml

Egypt - English - EDA (Egyptian Drug Authority)

european egyptian pharm. ind. - nasal spray - 100 mg/100ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

european egyptian pharmaceutical ind. co, egypt - fluticasone propionate - nasal drops, suspension - 0.05 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

european egyptian pharmaceutical ind. co, egypt - thiamine,pyridoxine,cyanocobalamin - coated tablet - 250,100,250 mg, µg,

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharco health sdn. bhd - lidocaine -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - european house dust mite extract, quantity: 6 sq-hdm; american house dust mite extract, quantity: 6 sq-hdm - tablet - excipient ingredients: gelatin; sodium hydroxide; purified water; mannitol - allergic rhinitis acarizax is indicated for the treatment of house dust mite (hdm) allergic rhinitis not well controlled despite use of symptom relieving medication in adults and adolescents (? 12 years). allergic asthma acarizax is indicated for the treatment of hdm allergic asthma not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis in adults. patients? asthma status should be carefully evaluated before the initiation of treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite extract, quantity: 5 ir/ml; american house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; phenol; sodium chloride; water for injections; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.